Impact of neonatal vitamin A supplementation on infant morbidity and mortality

J H Humphrey1, T Agoestina, L Wu

  • 1Division of Human Nutrition, Department of International Health, Baltimore, MD, USA.

Insights

Vitamin A supplementation at birth significantly reduced infant mortality by 64% in a placebo-controlled trial. This intervention also showed a trend towards decreasing severe respiratory infections in neonates.

Area of Science:

  • Neonatal Health
  • Nutritional Immunology
  • Public Health Interventions

Background:

  • Infant mortality and morbidity remain significant global health challenges.
  • Vitamin A deficiency is common in many developing regions, impacting immune function.
  • Early life nutrition plays a critical role in infant survival and development.

Purpose of the Study:

  • To evaluate the efficacy of single-dose oral vitamin A supplementation at birth in reducing infant mortality.
  • To assess the impact of neonatal vitamin A on infant morbidity, specifically common childhood illnesses.

Main Methods:

  • A randomized, placebo-controlled trial was conducted involving 2067 Indonesian neonates.
  • Infants received either 52 micromol (50,000 IU) of oral vitamin A or a placebo on their first day of life.
  • Infant mortality was tracked up to 1 year; morbidity was assessed in a subgroup up to 6 months.

Main Results:

  • Vitamin A supplementation was associated with a 64% reduction in infant mortality (Relative Risk = 0.36; 95% CI: 0.16, 0.87).
  • The protective effect on mortality was more pronounced in boys and infants with normal birth weight.
  • While immediate morbidity prevalence was similar, vitamin A-treated infants showed a trend towards fewer medical treatments for cough and fever.

Conclusions:

  • Single-dose neonatal vitamin A supplementation is a potentially effective strategy to decrease infant mortality rates.
  • The intervention may also reduce the incidence of severe respiratory infections in early infancy.
Abstract

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Vitamins01:30

Vitamins

Vitamins, derived from the Latin word for life, are essential organic substances required in small quantities for optimal growth and overall well-being. Unlike other organic nutrients, vitamins don't act as sources of energy or building materials but rather facilitate these nutrients' utilization by the body. Vitamins are predominantly coenzymes, assisting enzymes in specific chemical actions, like the oxidation of glucose for energy involving B vitamins. Most vitamins are not produced in our...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...